Stayble Therapeutics AB (publ) reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was SEK 0.138 million compared to SEK 0.029 million a year ago. Net loss was SEK 6.29 million compared to SEK 4.56 million a year ago. Basic loss per share from continuing operations was SEK 0.2 compared to SEK 0.33 a year ago.
For the full year, revenue was SEK 0.147 million compared to SEK 0.286 million a year ago. Net loss was SEK 23.74 million compared to SEK 24.53 million a year ago. Basic loss per share from continuing operations was SEK 0.92 compared to SEK 1.77 a year ago.